Efficacy and safety of combination therapy of tocilizumab and abatacept in patients with refractory systemic-onset juvenile idiopathic arthritis
Not Applicable
Recruiting
- Conditions
- Systemic-onset juvenile idiopathic arthritis(sJIA)
- Registration Number
- JPRN-UMIN000024178
- Lead Sponsor
- Yokohama City University Hospital Department of Pediatrics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1 Pulmonary tuberculosis, active bacterial infection or deep mycotic infection 2 Infection of HIV, HCV, HBV 3 Administration of live vaccine within 4 weeks 4 Cardiac dysfunction 5 Pregnant subjects or subjects who do not agree with contraception during the study period
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method